Neola Medical AB (OSTO:NEOLA) Debt-to-EBITDA : (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:NEOLA Neola Medical AB OSTO:NEOLA
21 GF Score
Price kr0.52
! 1 Warning Sign
View Full Analysis

What is Neola Medical AB Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Neola Medical AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was kr0.00 Mil. Neola Medical AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was kr0.00 Mil. Neola Medical AB's annualized EBITDA for the quarter that ended in Jun. 2026 was kr-13.50 Mil. Neola Medical AB's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Neola Medical AB's Debt-to-EBITDA or its related term are showing as below:

OSTO:NEOLA's Debt-to-EBITDA is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.64
* Ranked among companies with meaningful Debt-to-EBITDA only.

Neola Medical AB  (OSTO:NEOLA) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Neola Medical AB Debt-to-EBITDA Related Terms


Neola Medical AB Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Neola Medical AB's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neola Medical AB Debt-to-EBITDA Chart

Neola Medical AB Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-EBITDA
Get a 7-Day Free Trial - - - - -

Neola Medical AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

OSTO:NEOLA vs ABT, SYK, MDT: Debt-to-EBITDA Comparison

For the Medical Devices subindustry, Neola Medical AB's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neola Medical AB Debt-to-EBITDA vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Neola Medical AB's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Neola Medical AB's Debt-to-EBITDA falls into.


OSTO:NEOLA
21GF Score
Neola Medical AB OSTO:NEOLA
Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neola Medical AB Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Neola Medical AB's Debt-to-EBITDA for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -9.448
=0.00

Neola Medical AB's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -13.496
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.


Neola Medical AB Business Description

Address Scheelevagen 27, Ideon Science Park, Gateway 9th fl oor, Lund, SWE, 223 63
Neola Medical AB is revolutionizing neonatal intensive care with NEOLA, a medical device that can offer continuous lung monitoring and real-time alerts of life-threatening complications using a technology that measures lung volume changes and oxygen gas concentration. NEOLA has the potential to provide care, fewer days in intensive care, and healthier lives for preterm born infants. The company is building on a historic Swedish legacy of medical technology innovation and invaluable contributions to health care.
21GF Score

Get the complete analysis for OSTO:NEOLA

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.52
Price